All In Biotech

Drug Trial Radar · NCT06948318

A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

A Phase 3, Open-label, Multicenter Continuation Trial to Evaluate the Long-term Safety and Efficacy of Mezagitamab Subcutaneous Injection in Adults With Chronic Primary Immune Thrombocytopenia

Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Aug 14, 2025

Primary completion

Jul 29, 2029

Study completion Jul 29, 2029

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Apr 29, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary immune thrombocytopenia (ITP) is a condition where the immune system mistakenly destroys platelets, which are cells that help stop bleeding. This leads to a lower number of platelets, making it easier to bruise or bleed. The main aim of this study is to check how safe mezagitamab is and how well it is tolerated by adults with chronic primary ITP, if given over a longer time. Other aims are to learn how effective treatment with mezagitamab is and how the body processes it (called pharmacokinetics or PK) over a longer time. Participants of the following previous mezagitamab studies will be invited to join this continuation study: TAK-079-3002 and TAK-079-1004. In this continuation study, participants will receive mezagitamab when certain protocol criteria are met. During the study, participants will visit their study clinic several times.

Conditions

  • Immune Thrombocytopenic Purpura (ITP)

Interventions

  • MezagitamabDrug

    Mezagitamab injection administered SC.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEsTime frame: Up to approximately 108 weeks
  2. Number of Participants With TEAEs Leading to Permanent Withdrawal of MezagitamabTime frame: Up to approximately 108 weeks

Locations

118 sites in 15 countries. Site status is shown where the registry gives one.

  • Genesis Cancer and Blood Institute - SCRI

    Hot Springs, Arkansas · Not yet recruiting

  • USC Norris Comprehensive Cancer Center - Keck Medicine of USC

    Los Angeles, California · Not yet recruiting

  • University of California San Diego Center for Bleeding and Clotting Disorders

    San Diego, California · Not yet recruiting

  • Rocky Mountain Cancer Center

    Denver, Colorado · Withdrawn

  • Georgetown University Medical Center - Lombardi Comprehensive Cancer Center

    Washington D.C., District of Columbia · Not yet recruiting

  • Emory University

    Atlanta, Georgia · Not yet recruiting

  • Innovative Hematology, Inc.

    Indianapolis, Indiana · Not yet recruiting

  • The University of Iowa

    Iowa City, Iowa · Not yet recruiting

  • University Of Louisville Brown Cancer Center

    Louisville, Kentucky · Not yet recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • University of Massachusetts Chan Medical School

    Worcester, Massachusetts · Withdrawn

  • MidAmerica Cancer Center

    Kansas City, Missouri · Not yet recruiting

  • American Oncology Partners of Maryland, PA

    Morristown, New Jersey · Not yet recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Not yet recruiting

  • Montefiore Medical Center

    The Bronx, New York · Not yet recruiting

  • Duke University Hospital

    Durham, North Carolina · Not yet recruiting

  • East Carolina University

    Greenville, North Carolina · Not yet recruiting

  • Cleveland Clinic

    Cleveland, Ohio · Not yet recruiting

  • Oregon Health & Science University

    Portland, Oregon · Recruiting

  • Perelman Center for Advanced Medicine (PCAM) Hospital of The University of Pennsylvania Penn Blood Disorders Program

    Philadelphia, Pennsylvania · Not yet recruiting

  • Lewis Katz School of Medicine at Temple University

    Philadelphia, Pennsylvania · Not yet recruiting

  • Baylor College of Medicine

    Houston, Texas · Not yet recruiting

  • Virginia Oncology Associates

    Norfolk, Virginia · Not yet recruiting

  • University of Washingto

    Seattle, Washington · Not yet recruiting

  • Versiti Wisconsin, Inc

    Milwaukee, Wisconsin · Not yet recruiting

  • Canberra Hospital

    Garran, Australian Capital Territory, Australia · Recruiting

  • Concord Repatriation General Hospital

    Concord, New South Wales, Australia · Not yet recruiting

  • St George Hospital

    Kogarah, New South Wales, Australia · Recruiting

  • University of New South Wales (UNSW) - Liverpool Hospital - Liverpool Cancer Therapy Centre

    Liverpool, New South Wales, Australia · Recruiting

  • Westmead Hospital

    Westmead, New South Wales, Australia · Recruiting

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, Australia · Not yet recruiting

  • Monash University - Australian Centre for Blood Diseases (ACBD)

    Melbourne, Victoria, Australia · Recruiting

  • The Alfred Hospital

    Melbourne, Victoria, Australia · Recruiting

  • Fiona Stanley Hospital

    Murdoch, Western Australia, Australia · Recruiting

  • Perth Blood Institute

    West Perth, Western Australia, Australia · Recruiting

  • Medical Center "Fama Medical"

    Plovdiv, Bulgaria · Recruiting

  • UMHAT Sv. Ivan Rilski

    Sofia, Bulgaria · Recruiting

  • UMHAT SofiaMed, OOD

    Sofia, Bulgaria · Recruiting

  • University Multiprofile Hospital for Active Treatment - Prof. Dr. Stoyan Kirkovich AD

    Stara Zagora, Bulgaria · Not yet recruiting

  • Military Medical Academy Multiprofile Hospital for Active Treatment - Sofia

    Sofia, Sofia-Grad, Bulgaria · Recruiting

Showing 40 of 118 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.